1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) is sponsored by National Institutes of Health (NIH). This Funding Opportunity Announcement (FOA) solicits cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Frequently Asked Questions: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) | NCCIH U.S. Department of Health and Human Services National Institutes of Health Frequently Asked Questions: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) This frequently asked questions document includes questions and answers compiled to help researchers interested in a new National Institutes of Health (NIH) funding opportunity announcement (FOA) that solicits phased cooperative research applications to conduct clinical effectiveness research on the management of acute and/or chronic sickle cell disease (SCD) pain and ways to reduce reliance solely on opioid-based treatments and improve related psychological and functional outcomes.
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) RFA-AT-23-002 The receipt date for applications is November 21, 2022. General Terms and Definitions 1. What is the U mechanism?
The U mechanism, or cooperative agreement, is a support mechanism intermediate between a grant and a contract in how it is handled. It is used when there will be substantial Federal scientific or programmatic involvement in the initiative once the award is made. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.
Awards made to this funding opportunity will be cooperative agreements. 2. What is the NIH HEAL Initiative, and how does this FOA support the objectives of HEAL?
The NIH Helping to End Addiction Long-term ® Initiative, or NIH HEAL Initiative ® , is an effort to speed scientific solutions to stem the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the NIH HEAL Initiative is available at heal.
nih. gov . The overall goal of this program is to inform clinicians about the effectiveness of interventions such as coordinated, multidisciplinary management strategies that reduce acute and/or chronic SCD pain and that continue to provide access to opioid pain management as needed.
Clinical trials in this program will be conducted within the infrastructure of the HEAL Pain Management Effectiveness Research Network (HEAL ERN). 3. What is “effectiveness” research?
Clinical efficacy or effectiveness research aims to evaluate whether interventions improve clinical and/or functional health outcomes in ways that are significant for patients, clinicians, and other decisionmakers. These research studies may utilize various control groups including, but not limited to, placebo, sham conditions, time and attention, active comparison, or usual care controls.
Frequently Asked Questions: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
According to the current listing, eligibility includes: County governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Private institutions of higher education; Public housing author…. Confirm the full requirements in the official notice before applying.
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article